Physician profile
Keith Brenner
NPI 1316139686
$5,561.96
in general payments reported to CMS, 2019-2025
30 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,300 · 2022: $222 · 2023: $976 · 2024: $1,670 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,039.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,903.74 | 2021-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals Lp | $878.75 | 2022-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $817.60 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pulmonx Corporation | $266.94 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| La Jolla Pharmaceutical Company | $172.43 | 2024-2025 | Giapreza |
| Mylan Specialty L.P. | $158.94 | 2022-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $151.18 | 2023-2025 | Glassia, Entyvio |
| Ambu INC. | $114.60 | 2025 | |
| Amgen INC. | $103.69 | 2023-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $97.64 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Intuitive Surgical, INC. | $89.18 | 2024 | |
| Verona Pharma, INC. | $84.68 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $79.46 | 2025 | Yupelri |
| United Therapeutics Corporation | $74.21 | 2022-2023 | Tyvaso |
| Philips North America LLC | $72.57 | 2022-2025 | Vest Therapy Und |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $60.05 | 2023-2024 | Impella |
| Grifols USA, LLC | $57.80 | 2022-2023 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $54.53 | 2023-2025 | Dupixent |
| W. L. Gore & Associates, INC. | $50.70 | 2022 | |
| Mindray Ds USA, INC. | $44.81 | 2024 | Te7 Max, Te X |
| Insmed, INC. | $37.06 | 2025 | Arikayce, Brinsupri |
| Pfizer INC. | $36.00 | 2023-2024 | |
| Inspire Medical Systems, INC. | $33.55 | 2025 | Inspire |
| Genzyme Corporation | $31.07 | 2024-2025 | |
| Boston Scientific Corporation | $23.08 | 2024 | Exalt Model D |
| Lilly USA, LLC | $19.97 | 2025 | Zepbound |
| Merz Pharmaceuticals, LLC | $18.40 | 2024 | Inbrija, Xeomin |
| Teva Pharmaceuticals USA, INC. | $15.16 | 2022 | |
| Vivus LLC | $14.17 | 2023 | Qsymia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.